GlycoRNAs are small noncoding RNA molecules that carry sugar chains (glycans) and sit on the outer surface of living cells, a combination that, until 2021, nobody thought existed. The discovery upended a basic assumption in biology: that only proteins and lipids get decorated with sugars. GlycoRNAs appear to participate in immune signaling, cell-to-cell communication, and possibly viral infection, making them one of the more surprising finds in recent molecular biology.
How GlycoRNAs Were Discovered
The story begins with a technique called metabolic labeling, where researchers feed cells modified sugar molecules tagged with a chemical handle. When Ryan Flynn and colleagues at Stanford used this approach, they expected to see signals only on proteins and lipids. Instead, they kept picking up sugar-tagged signals on purified RNA, even after stripping away all proteins. The signals appeared across a strikingly wide range of cell types: human cervical cancer cells, embryonic stem cells, leukemia cell lines, mouse immune cells, and hamster ovary cells.
The team’s 2021 paper in Cell confirmed that conserved small noncoding RNAs carry sialylated glycans, that these glycoRNAs depend on the cell’s normal sugar-building machinery for assembly, and that they are enriched in sialic acid and fucose, two sugars commonly found on cell-surface proteins.1Cell. Small RNAs are modified with N-glycans and displayed on the surface of living cells Most glycoRNAs turned out to be sitting on the outside of the cell, where they could interact with immune receptors called Siglecs and with antibodies that recognize double-stranded RNA. A companion commentary described the finding as evidence that, like proteins and lipids, conserved noncoding RNAs are functionalized with carbohydrates.2Cell. A glimpse at the glycoRNA world
Where the Sugar Meets the RNA
One of the biggest open questions after the initial discovery was exactly how a sugar chain physically attaches to an RNA molecule. Proteins have well-known attachment points for glycans, but RNA has a different chemical backbone, and the connection was unclear for several years. In 2024, two groups converged on the answer: a modified RNA base called acp3U, short for 3-(3-amino-3-carboxypropyl)uridine. This modified nucleoside turned out to be the anchor point where N-glycans latch onto RNA.
The identification came through a method combining periodate oxidation with mass spectrometry. Researchers found that acp3U was the most enriched glycan-bearing nucleoside across multiple human cell lines, and they confirmed the linkage by synthesizing a standard molecule (acp3U connected to a single sugar unit called GlcNAc) and showing it matched what they pulled out of cells.3PubMed Central. The modified RNA base acp3U is an attachment site for N-glycans in glycoRNA The identification of acp3U has been called a major breakthrough in establishing glycoRNA as a structurally defined biopolymer, not just a curiosity.4PubMed. Potential Nucleotide Sites for RNA Glycosylation: acp3U and Beyond Whether acp3U is the only attachment site or just the predominant one remains an active question. Other modified uridine bases are being investigated as possible additional glycan anchors.
How GlycoRNAs Get Built
Cells build sugar chains on proteins using a well-choreographed assembly line that runs through two compartments: the endoplasmic reticulum (ER) and the Golgi apparatus. Enzymes in these compartments add sugars step by step, trimming and extending the chains until the finished glycoprotein heads to the cell surface. GlycoRNA biosynthesis appears to borrow at least some of this same machinery, but how RNA molecules access it is genuinely puzzling, because RNA is not normally found inside the ER or Golgi.
Experimental work has shown that disrupting the oligosaccharyltransferase (OST) complex, a key enzyme in protein glycosylation, reduces the amount of sialylated glycoRNA on the cell surface. Changes to other N-glycan processing enzymes also alter glycoRNA levels, pointing to a regulatory link between the protein glycosylation pathway and RNA glycosylation.5PubMed. Processing of N-glycans in the ER and Golgi influences the production of surface sialylated glycoRNA Several hypotheses try to explain how RNA reaches these enzymes. One idea is that RNA-binding proteins escort RNA molecules into or near the ER and Golgi. Another suggests unusual vesicular transport routes could shuttle RNA-containing complexes past the glycosylation machinery. A third proposes that the RNA-binding proteins themselves get translated locally near the ER and pick up their RNA cargo close to the glycosylation enzymes.6PubMed Central. GlycoRNA: A new player in cellular communication None of these has been definitively proven, and the biogenesis pathway remains one of the field’s biggest unsolved problems.
Life on the Cell Surface
GlycoRNAs do not simply float randomly across the outer membrane. Recent work has revealed that they organize into nanoclusters together with cell-surface RNA-binding proteins (csRBPs). These clusters are well-defined structures, not random aggregates, and they can be disrupted by adding RNase (an enzyme that chews up RNA) to the outside of cells. The clustering suggests an organized layer of RNA and protein on the cell exterior that helps regulate how cells communicate with their environment.7Cell. Cell-surface RNA-binding proteins form functional nanoclusters enriched for glycoRNAs
Beyond the cell surface itself, glycoRNAs have been detected on exosomes, tiny vesicles that cells release into the surrounding fluid and bloodstream. Using a combination of chemical labeling and super-resolution microscopy, researchers confirmed that glycoRNAs sit on the outside of exosomes and that the glycan-RNA linkage survives the journey outside the cell. Enzymatic treatments confirmed the location and stability of these modifications, hinting that glycoRNAs on exosomes could play a role in intercellular communication over longer distances.8PubMed Central. Mapping GlycoRNAs on an Exosomal Surface
The specific RNA species that carry glycans are not messenger RNAs or the big ribosomal RNAs you might associate with gene expression. They are small noncoding RNAs, including snRNAs (like U1, U3, and U8), snoRNAs (like U35a), and Y RNAs (like Y5). These molecules were already known for their roles inside the cell, particularly in RNA splicing and ribosome assembly. Finding them decorated with sugars and parked on the cell exterior was unexpected. New imaging tools have made it possible to track individual glycoRNA species on single cells, revealing that different cell types carry distinct glycoRNA signatures.9Nucleic Acids Research. In situ tracking of glycoRNAs on single-cell surface to reveal RNA heterogeneity and transport mechanism
Talking to the Immune System
The sialic acid coating on glycoRNAs is not just a chemical decoration. Sialic acid is the very sugar that Siglec receptors on immune cells are designed to recognize. Siglecs are a family of receptors found on white blood cells, and many of them send inhibitory signals when engaged, essentially telling the immune cell to stand down. The fact that glycoRNAs carry sialic acid and can bind Siglecs immediately raised the possibility that glycoRNAs help regulate immune responses.
Several Siglec family members have now been identified as glycoRNA receptors. Flow cytometry and immunoprecipitation experiments identified Siglec-5 as a binding partner for glycoRNAs, and this interaction was shown to mediate monocyte adhesion.10PubMed Central. GlycoRNA-L and glycoRNA-S mediate human monocyte adhesion via binding to Siglec-5 In neuronal cells, Siglec-11 binding to cell-surface glycoRNAs was significantly reduced when the cell surface was treated with RNase, confirming that the RNA component is essential for Siglec-11 engagement. This interaction suppressed neuroinflammation, suggesting a protective role.11Cell Chemical Biology. GlycoRNAs suppress neuroinflammation via the Siglec-11 axis More broadly, glycoRNAs are now thought to influence RNA stability, localization, and interactions with glycan-binding proteins like Siglecs and selectins, challenging the traditional view that glycosylation is strictly a protein and lipid affair.12PubMed. The emerging role of GlycoRNAs in immune regulation and recognition
GlycoRNAs in Cancer
Tumor cells are notorious for remodeling their sugar coats to dodge immune surveillance. They often ramp up sialic acid on their surfaces, which engages inhibitory Siglec receptors on immune cells and helps the tumor hide. GlycoRNAs fit neatly into this picture. Emerging evidence links glycoRNAs on tumor cells to three interconnected processes: immune escape, intercellular adhesion, and metastatic spread. By acting as surface ligands for Siglecs and P-selectin, glycoRNAs may help tumors suppress immune attack while also facilitating the cell-to-cell sticking that promotes metastasis.13PubMed. Role of glycosylated small noncoding RNAs in tumor: mechanism, function and clinical significance
The presence of glycoRNAs on tumor-derived exosomes adds a diagnostic angle. Tumor exosomes circulate in the bloodstream, and because they are abundant and stable, they are attractive targets for liquid biopsy. Researchers have used specialized assays to measure five specific glycoRNAs (U1, U3, U35a, U8, and Y5) on exosomes from cancer patients’ serum. The combined signature of these five glycoRNAs distinguished cancer patients from healthy controls and could further separate different cancer types. Unsupervised clustering of glycoRNA patterns clearly separated patient groups, suggesting that glycoRNA profiling could become a useful diagnostic tool.14Protein & Cell. GlycoRNA research: from unknown unknowns to known unknowns
Viruses and the Cell Surface RNA Layer
The discovery that RNA molecules sit on the outside of cells raised an immediate question for virologists: could viruses exploit them? Early evidence suggests yes. In experiments with human alveolar epithelial cells, treating the cell surface with RNase reduced the binding of fluorescently labeled influenza virus particles, implying that cell-surface glycoRNA contributes to barrier function in the lungs and may serve as an adhesion molecule for the virus.15American Journal of Respiratory Cell and Molecular Biology. Cell Surface RNA Expression Modulates Alveolar Epithelial Function More broadly, glycoRNAs on host cell surfaces may act as adhesive molecules that viruses hijack during entry, and they may also interact with immunomodulatory receptors involved in the immune response to infection.16PubMed Central. GlycoRNAs: Biological functions and novel antiviral targets Whether targeting glycoRNAs could become an antiviral strategy is speculative at this stage, but the connection between this cell-surface RNA layer and viral entry is a thread researchers are actively pulling.
Growth Factor Signaling and the Extracellular Matrix
GlycoRNAs do not operate in isolation on the cell surface. They cluster with heparan sulfate, a sugar-rich molecule that studs the outer surface of most cells and is already known to help regulate growth factor signaling. Research has shown that VEGF-A, a growth factor critical for blood vessel formation, interacts selectively with glycoRNAs through the same region it uses to bind heparan sulfate. Functionally, cell-surface RNAs regulate how growth factor signals get transmitted across the membrane, adding a previously unknown control layer to a well-studied signaling pathway.17bioRxiv. Cell surface ribonucleoproteins cluster with heparan sulfate to regulate growth factor signaling VEGF-A was identified as a new noncanonical cell-surface RNA-binding protein, with its arginine-rich heparan sulfate binding domain doing double duty by also grabbing RNA. This finding places glycoRNAs squarely within the extracellular matrix, not just the plasma membrane, and expands the potential scope of what they influence.18PubMed. Functional Inclusion of RNA Biology in the Tethered Extracellular Matrix
The Skeptics and the Contamination Question
Not everyone in the field is convinced that every reported glycoRNA signal represents a genuine covalent glycan-RNA molecule. A 2024 preprint raised an important methodological concern: non-RNA glycoconjugates (sugar-carrying molecules that are not RNA) persist through standard RNA purification steps, including both phenol-chloroform extraction and silica-column methods. In most biochemical assays, these contaminants behave almost identically to what has been described for glycoRNA, showing the same sensitivity to enzymes and the same migration patterns on gels. The critical difference is that these glycoconjugates survive RNase digestion, meaning they are not actually RNA. However, the authors found that a silica column cleanup step performed after RNase treatment, a step included in published glycoRNA protocols, removes the non-RNA signals in a way that can look like RNase destroyed them, when in reality the column simply washed them away.19bioRxiv. RNA-associated glycoconjugates highlight potential ambiguities in glycoRNA analysis
This is a legitimate concern, and the glycoRNA field has responded by developing more rigorous detection methods. The identification of acp3U as a defined attachment site, along with mass spectrometry confirmation of the glycan-nucleoside linkage, provides chemical evidence that goes beyond the early biochemical assays that the preprint critiqued. Newer imaging approaches that label both the glycan and RNA components simultaneously on intact cells also help distinguish genuine glycoRNAs from co-purifying contaminants. The debate is a healthy part of a young field working out which signals are real and which are artifacts, but the weight of evidence, including direct chemical identification of the glycan-nucleoside bond, has grown considerably since 2021.
How Researchers Detect GlycoRNAs
Studying glycoRNAs requires tools that can see both the sugar and the RNA at once, which is trickier than it sounds. The original discovery relied on metabolic labeling: feeding cells an unnatural sugar bearing a chemical handle, then using click chemistry to attach a fluorescent or affinity tag to any molecule that incorporated the sugar. After purifying RNA away from proteins, any remaining signal indicated glycosylated RNA. A published protocol details this approach combined with northwestern blotting, a technique adapted to detect labeled RNA species on a membrane.20PubMed Central. Protocol for detecting glycoRNAs using metabolic labeling and northwestern blot
A newer sequencing-based method called rPAL-seq takes things further. It selectively captures RNAs bearing sialic acid, then sequences them to identify which RNA species are glycosylated. The method works with less than 100 nanograms of input RNA, a roughly 50-fold improvement in sensitivity over earlier approaches. When applied across 13 human cell lines, rPAL-seq found lineage-specific glycoRNA patterns alongside a conserved core dominated by uridine-rich snRNAs and snoRNAs, with modification signatures pointing to glycosylation on acp3U or related uridine-based modifications.21bioRxiv. Catch and release of sialoglycoRNAs enables sequencing-based profiling across cellular and extracellular material For single-cell imaging, a system called GLINT uses proximity-based DNA circuits to visualize specific glycoRNAs on individual cells, revealing cell-to-cell variation in glycoRNA composition that bulk methods miss.22Nucleic Acids Research. In situ tracking of glycoRNAs on single-cell surface to reveal RNA heterogeneity and transport mechanism
What Remains Unknown
For all the progress since 2021, the glycoRNA field has more open questions than settled ones. The biogenesis pathway is the most glaring gap: researchers know the cell’s standard glycosylation machinery is involved, but nobody has yet traced the full route an RNA molecule takes from the nucleus to the cell surface with its sugar coat intact. The stoichiometry is also unclear, meaning it is not yet known what fraction of any given small noncoding RNA species carries glycans at any moment, or whether glycosylation is an all-or-nothing modification or a graded one.
Functional understanding is still largely correlational. GlycoRNAs bind Siglecs, and Siglec engagement has immune consequences, but the specific downstream signaling cascades triggered by glycoRNA-Siglec interactions (as distinct from glycoprotein-Siglec interactions) have not been fully mapped. Whether glycoRNAs carry unique information that proteins and lipids do not, or whether they simply add more copies of the same sialic acid “self” signal, is an important distinction that remains unresolved. The cancer biomarker work is promising but early: the studies showing distinct glycoRNA profiles in patient serum need validation in larger, blinded cohorts before clinical use becomes realistic. And the influenza adhesion finding, while intriguing, comes from in vitro experiments on cultured lung cells and has not yet been tested in animal models of infection. The field is moving fast, with new papers appearing monthly, but the honest assessment is that glycoRNA biology is still closer to its beginning than its middle.